Research programme: glycogen synthase kinase 3 inhibitors - Chiron

Drug Profile

Research programme: glycogen synthase kinase 3 inhibitors - Chiron

Alternative Names: CHIR 118637; CHIR 9803; CHIR 99021; CT 98023; CY 20026; Glycogen synthase kinase 3 inhibitors research programme - Chiron

Latest Information Update: 29 Aug 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chiron Corporation
  • Class
  • Mechanism of Action Glycogen synthase kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 29 Aug 2003 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 29 Oct 2002 A preclinical study has been added to the Diabetes pharmacodynamics and pharmacokinetics sections
  • 20 Dec 2000 Preclinical development for Type-2 diabetes mellitus in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top